Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...

CAMBRIDGE, Mass., April 23, 2025 /PRNewswire/ -- Repertoire(R) Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, ...

HOUSTON – (Jan. 10, 2025) – A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators from ...

When a T cell encounters a cell carrying pieces of a virus or bacteria, the two form a tight contact point known as an immune ...

Please provide your email address to receive an email when new articles are posted on . Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease ...

Researchers combined advanced imaging techniques with a computational method to probe how immune cells interact with each other, revealing that the interactions between immune cells in the vicinity of ...

Company refocusing on the potential of its DECODE™ Platform to develop transformative immune medicines CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire® Immune Medicines announced today that Torben ...

Repertoire Immune Medicines Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to discover and develop innovative T cell-targeted immune ...

A study shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators examined how molecular dynamics at the immune synapse -- where ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators from Baylor College of Medicine, ...